Scholar Rock Holding Corp is a pioneering biopharmaceutical firm based in Cambridge, Massachusetts, dedicated to crafting innovative medicines for severe diseases where protein growth factor signaling is key. Its leading product, Apitegromab, targets spinal muscular atrophy and has reached Phase 3 clinical trials. Additionally, the company is exploring SRK-181 for certain cancer treatments resistant to existing therapies and is developing treatments for neuromuscular disorders, cancer, fibrosis, and anemia. Scholar Rock collaborates with Gilead Sciences to tackle fibrotic diseases, showcasing its commitment to addressing complex medical challenges.
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised…
In the past week or so, a fintech firm and two biotechs saw some huge insider buying. However, these were not the only notable insider purchases recently.
People don’t like to throw money into a sinking ship, and by that logic, insider buys in Wall Street can be an easy way to gauge how well a company might do…
